文献速递白血病淋巴瘤浆细胞疾病

超越最高分级:血液系统恶性肿瘤不良事件评估与报告的现代化

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.
PubMed 文献 · Lancet Haematol · 2018-06-18

本委员会由国际多学科专家组对血液系统恶性肿瘤不良事件评估进行批判性审视,指出需纳入患者报告结局、关注干细胞移植与生存者问题、应对监管审批挑战并评估真实世界患者毒性,提出了一系列优先问题和潜在解决方案。

要点

  • 血液肿瘤治疗进展使多种疾病转为慢性病,需长期持续治疗并关注独特副作用。
  • 当前不良事件评估需纳入患者报告结局,并关注干细胞移植与生存者相关问题。
  • 委员会识别了不良事件评估的优先问题并定义了潜在解决方案。

核心结论

  • 委员会旨在通过批判性审视当前不良事件评估流程、强调纳入患者报告结局的必要性、解决干细胞移植与生存者特有问题、评估监管审批挑战及真实世界患者毒性,来改善血液系统恶性肿瘤临床试验中的毒性评估。

研究设计与样本

  • 本委员会由代表广泛学术与临床肿瘤专业知识的国际临床医生、临床研究者、方法学家、监管人员和患者倡导者组成,审视血液系统恶性肿瘤中的不良事件。

主要发现

  • 过去二十年血液系统恶性肿瘤治疗与结局取得巨大进展,侵袭性恶性肿瘤治愈率提高,慢性髓系白血病、慢性淋巴细胞白血病、惰性B细胞淋巴瘤和多发性骨髓瘤的5年生存率显著改善。
  • 多种血液系统恶性肿瘤现已成为慢性疾病,采用持续给药治疗,具有随时间推移的独特副作用。
  • 本文审视的不良事件评估问题与多种恶性肿瘤相关,迄今在血液学背景下探索不足。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly. This improvement is a result of substantial changes in disease management strategies in these malignancies. Several haematological malignancies are now chronic diseases that are treated with continuously administered therapies that have unique side-effects over time. In this Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates representing a broad range of academic and clinical cancer expertise examine adverse events in haematological malignancies. The issues pertaining to assessment of adverse events examined here are relevant to a range of malignancies and have been, to date, underexplored in the context of haematology. The aim of this Commission is to improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, addressing issues unique to stem-cell transplantation and survivorship, appraising challenges in regulatory approval, and evaluating toxicity in real-world patients. We have identified a range of priority issues in these areas and defined potential solutions to challenges associated with adverse event assessment in the current treatment landscape of haematological malignancies.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018. PMID: 29907552. doi:10.1016/S2352-3026(18)30051-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。